Prospective pilot study to investigate the one-Abutment-one-time procedure concerning the periimplant tissue.

Prospective pilot study to investigate the one-Abutment-one-time procedure concerning the periimplant tissue. - OAT-IMP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013174

Enrollment

Registered

2017-10-27

Start date

2017-11-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K08.1

Interventions

Group 1: Patients who have been treated with the one-abutment-one-time procedure after implantation are invited to a control under investigation. In doing so, the following study-relevant data are c

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. One-abutment-one-time concept (arm1, this is an exclusion criteria for arm 2, arm 2 inclusion criteria are gingivaformer) 2. Possibility of follow-up appointment 3. Implant exposure between January 2013 and December 2016 4. Existing X-ray images of implant insertion and exposure 5. Documentation complete 6. Single tooth implant 7. Natural mesial neighboring tooth, healthy or adequately restored 8. Not integrated into other clinical trial 9. Implant in situ

Exclusion criteria

Exclusion criteria: 1. Supply via provisional abutment (arm1, inclusion criteria for arm 2) 2. Patients can not be reached anymore 3. Implant exposure outside the examination period 4. X-ray documentation incomplete 5. Documentation incomplete 6. Restored as anchor implant with implant / compound bridge 7. Missing / deeply destroyed / insufficiently restored adjacent teeth 8. Implant no longer in situ

Design outcomes

Primary

Measure	Time frame
Differences in the health of the peri-implant tissue of two different implant care concepts assessed by biomarkers and enzymes from peri-implant crevicular fluid (PICF), probing depths, papillary bleeding index and bone degradation during follow-up at the time of study	—

Secondary

Measure	Time frame
In the evaluation of the PICF measurement the inflammation marker calprotectin will be determined in addition to the established marker MMP-8,. Calprotectin has been established as a inflammation marker for the oral area in the Department of Prosthetic Dentistry at Ulm University Clinic. A comparison of the two markers shall be presented.	—

Countries

Germany

Contacts

Public ContactAnna-Sophia Louise Ehleiter

Klinik für Zahnärztliche Prothetik Universitätsklinikum Ulm

annasophia.ehleiter@uniklinik-ulm.de0731 500 64222

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026